Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis

Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis

Various papers have introduced the use of positron emission tomography (PET) with [<sup>68</sup>Ga]Ga-radiolabeled fibroblast-activation protein inhibitor (FAPi) radiopharmaceuticals in different subtypes of gastric cancer (GC). Our aim was to assess the diagnostic performance of this no...

Full description

Bibliographic Details
Main Authors:	Alessio Rizzo, Manuela Racca, Federico Garrou, Elisabetta Fenocchio, Luca Pellegrino, Domenico Albano, Francesco Dondi, Francesco Bertagna, Salvatore Annunziata, Giorgio Treglia
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	International Journal of Molecular Sciences
Subjects:	FAPi fibroblast-activating protein inhibitor PET positron emission tomography gastric cancer stomach
Online Access:	https://www.mdpi.com/1422-0067/24/12/10136

Similar Items

Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review
by: Alessio Rizzo, et al.
Published: (2024-03-01)

Diagnostic Accuracy of [<sup>68</sup>Ga]Ga Labeled Fibroblast-Activation Protein Inhibitors in Detecting Head and Neck Cancer Lesions Using Positron Emission Tomography: A Systematic Review and a Meta-Analysis
by: Alessio Rizzo, et al.
Published: (2023-11-01)

Emerging Role of FAPI PET Imaging for the Assessment of Benign Bone and Joint Diseases
by: Francesco Dondi, et al.
Published: (2022-08-01)

Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [<sup>18</sup>F]F-FDG in Oncology: A Systematic Review
by: Giorgio Treglia, et al.
Published: (2021-10-01)

Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis
by: Alessio Rizzo, et al.
Published: (2022-11-01)

Highlighting Fibroblasts Activation in Fibrosis: The State-of-The-Art Fibroblast Activation Protein Inhibitor PET Imaging in Cardiovascular Diseases
by: Yan Cui, et al.
Published: (2023-09-01)

Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics—Where We Are at and Where We Are Heading: A Systematic Review
by: Marko Magdi Abdou Sidrak, et al.
Published: (2023-02-01)

Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET
by: Laura Gilardi, et al.
Published: (2022-02-01)

Relationship between Baseline [<sup>18</sup>F]FDG PET/CT Semiquantitative Parameters and BRCA Mutational Status and Their Prognostic Role in Patients with Invasive Ductal Breast Carcinoma
by: Francesco Dondi, et al.
Published: (2022-10-01)

PET/CT with Fibroblast Activation Protein Inhibitors in Breast Cancer: Diagnostic and Theranostic Application—A Literature Review
by: Silvia Taralli, et al.
Published: (2023-01-01)

Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography
by: Aleksander Kosmala, et al.
Published: (2022-05-01)

The Role of [<sup>68</sup>Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review
by: Domenico Albano, et al.
Published: (2022-08-01)

Imaging Inflammation with Positron Emission Tomography
by: Janette Iking, et al.
Published: (2021-02-01)

Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review
by: Alessio Rizzo, et al.
Published: (2023-02-01)

Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis
by: Barbara Muoio, et al.
Published: (2022-07-01)

PET/CT and Conventional Imaging for the Assessment of Neuroendocrine Prostate Cancer: A Systematic Review
by: Francesco Dondi, et al.
Published: (2023-09-01)

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74
by: Frederik M. Glatting, et al.
Published: (2022-10-01)

The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review
by: Alessio Rizzo, et al.
Published: (2023-01-01)

Advances in the Development of Positron Emission Tomography Tracers for Improved Detection of Differentiated Thyroid Cancer
by: Hannelore Iris Coerts, et al.
Published: (2024-04-01)

The Role of PSMA PET Imaging in the Classification of the Risk of Prostate Cancer Patients: A Systematic Review on the Insights to Guide an Active Surveillance Approach
by: Francesco Dondi, et al.
Published: (2024-03-01)

FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature
by: Priscilla Guglielmo, et al.
Published: (2024-02-01)

FAP-targeted PET imaging in gastrointestinal malignancies: a comprehensive review
by: Ayça Arçay Öztürk, et al.
Published: (2023-08-01)

Prevalence of Brain Incidental Lesions Detected by <sup>68</sup>Ga-DOTA Peptides PET/CT
by: Domenico Albano, et al.
Published: (2022-07-01)

The Superiority of Fibroblast Activation Protein Inhibitor (FAPI) PET/CT Versus FDG PET/CT in the Diagnosis of Various Malignancies
by: Yanzhao Dong, et al.
Published: (2023-02-01)

Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [<sup>18</sup>F]FAPI-74 with [<sup>18</sup>F]FDG in Patients with PDAC: A Prospective Exploratory Study
by: Emil Novruzov, et al.
Published: (2023-05-01)

Delayed 68Ga-FAPI-46 PET/MR imaging confirms ongoing fibroblast activation in patients after acute myocardial infarction
by: Jana Kupusovic, et al.
Published: (2024-02-01)

Performance and Prospects of [<sup>68</sup>Ga]Ga-FAPI PET/CT Scans in Lung Cancer
by: Paula E. Borgonje, et al.
Published: (2022-11-01)

Two Birds with One Stone: Skull Base Meningioma and Jugulotympanic Paragangliomas with Somatostatin Receptor Positron Emission Tomography
by: Giorgio Treglia, et al.
Published: (2021-09-01)

Preparation of <sup>18</sup>F-Labeled Tracers Targeting Fibroblast Activation Protein via Sulfur [<sup>18</sup>F]Fluoride Exchange Reaction
by: Austin Craig, et al.
Published: (2023-12-01)

Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature
by: Priscilla Guglielmo, et al.
Published: (2023-08-01)

FAPI PET/CT Imaging—An Updated Review
by: Kunal Ramesh Chandekar, et al.
Published: (2023-06-01)

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?
by: Katharina Dendl, et al.
Published: (2021-09-01)

Head-to-head comparison of 18F-FAPI and 18F-FDG PET/CT in staging and therapeutic management of hepatocellular carcinoma
by: Jing Zhang, et al.
Published: (2023-10-01)

FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century
by: Rong Huang, et al.
Published: (2022-05-01)

The “Undetermined Significance” of <sup>18</sup>F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)
by: Giorgio Treglia, et al.
Published: (2021-08-01)

<sup>18</sup>F-FDG PET/CT Maximum Tumor Dissemination (Dmax) in Lymphoma: A New Prognostic Factor?
by: Domenico Albano, et al.
Published: (2023-04-01)

Novel <sup>68</sup>Ga-Labeled Pyridine-Based Fibroblast Activation Protein-Targeted Tracers with High Tumor-to-Background Contrast
by: Arsyangela Verena, et al.
Published: (2023-03-01)

Signet cell rectal carcinoma with prostatic involvement detected by FAPI-04 PET-MRI fusion
by: K. Arun Prashanth, et al.
Published: (2023-12-01)

Molecular imaging of fibroblast activation in multiple non-ischemic cardiomyopathies
by: Jingnan Wang, et al.
Published: (2023-05-01)

Comparison between Two Different Scanners for the Evaluation of the Role of <sup>18</sup>F-FDG PET/CT Semiquantitative Parameters and Radiomics Features in the Prediction of Final Diagnosis of Thyroid Incidentalomas
by: Francesco Dondi, et al.
Published: (2022-01-01)